Potential cardiovascular benefits of GLP-1 analogues: evidence and implications for type 2 diabetes management

  • M Vally University of the Witwatersrand
Keywords: Type 2 Diabetes, GLP-1 analogues, LEADER, SUSTAIN-6, ELIXA, Liraglutide, Semaglutide

Abstract

Glucagon-like peptide-1 (GLP-1) analogues are an injectable therapy used in the management of type 2 diabetes. These drugs seem to reduce cardiovascular risk factors and clinical trial data seems to suggest that liraglutide and semaglutide reduce cardiovascular risk in patients with type 2 diabetes and concomitant atherosclerotic cardiovascular disease. The search for agents such as these (and SGLT2 inhibitors) that not only manage diabetes but also reduce cardiovascular risk has resulted in a paradigm shift in the way diabetes can be managed.

Author Biography

M Vally, University of the Witwatersrand

Division of Pharmacology, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, South Africa

Published
2020-04-17
Section
Review